1. Home
  2. DVAX vs PLYM Comparison

DVAX vs PLYM Comparison

Compare DVAX & PLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • PLYM
  • Stock Information
  • Founded
  • DVAX 1996
  • PLYM 2011
  • Country
  • DVAX United States
  • PLYM United States
  • Employees
  • DVAX N/A
  • PLYM N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • PLYM Real Estate Investment Trusts
  • Sector
  • DVAX Health Care
  • PLYM Real Estate
  • Exchange
  • DVAX Nasdaq
  • PLYM Nasdaq
  • Market Cap
  • DVAX 1.2B
  • PLYM 981.1M
  • IPO Year
  • DVAX 2004
  • PLYM 2017
  • Fundamental
  • Price
  • DVAX $10.15
  • PLYM $21.84
  • Analyst Decision
  • DVAX Buy
  • PLYM Hold
  • Analyst Count
  • DVAX 4
  • PLYM 7
  • Target Price
  • DVAX $26.50
  • PLYM $20.83
  • AVG Volume (30 Days)
  • DVAX 1.7M
  • PLYM 804.4K
  • Earning Date
  • DVAX 11-06-2025
  • PLYM 11-05-2025
  • Dividend Yield
  • DVAX N/A
  • PLYM 4.37%
  • EPS Growth
  • DVAX N/A
  • PLYM 439.08
  • EPS
  • DVAX N/A
  • PLYM 2.89
  • Revenue
  • DVAX $316,268,000.00
  • PLYM $171,801,000.00
  • Revenue This Year
  • DVAX $23.23
  • PLYM $1.88
  • Revenue Next Year
  • DVAX $16.57
  • PLYM $9.24
  • P/E Ratio
  • DVAX N/A
  • PLYM $7.61
  • Revenue Growth
  • DVAX 26.66
  • PLYM N/A
  • 52 Week Low
  • DVAX $9.20
  • PLYM $12.70
  • 52 Week High
  • DVAX $14.63
  • PLYM $22.65
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 52.11
  • PLYM 62.68
  • Support Level
  • DVAX $9.95
  • PLYM $21.98
  • Resistance Level
  • DVAX $10.35
  • PLYM $22.60
  • Average True Range (ATR)
  • DVAX 0.29
  • PLYM 0.36
  • MACD
  • DVAX 0.08
  • PLYM -0.21
  • Stochastic Oscillator
  • DVAX 75.00
  • PLYM 47.24

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About PLYM Plymouth Industrial REIT Inc.

Plymouth Industrial REIT Inc is a full-service, vertically integrated, self-administered, and self-managed Maryland corporation. It is focused on the acquisition, ownership, and management of single and multi-tenant Class B industrial properties, including distribution centers, warehouses, and light industrial properties, located in secondary and primary markets across the United States. The company has one reportable segment, which is Industrial properties. The majority of its property portfolio is spread across Florida, Ohio, Indiana, Tennessee, Illinois and Georgia, among others. It receives income from the rental revenue through its properties.

Share on Social Networks: